2016 ACC AHA HFSA Guideline Update

Accepted Manuscript
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart

Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart
Failure
Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair, Writing Committee
Member, Mariell Jessup, MD, FACC, FAHA, FESC, Vice Chair, Writing Committee
Member, Biykem Bozkurt, MD, PhD, FACC, FAHA, Writing Committee Member,
Javed Butler, MD, MBA, MPH, FACC, FAHA, Writing Committee Member, Donald E.
Casey, Jr., MD, MPH, MBA, FACC, Writing Committee Member, Monica M. Colvin,
MD, FAHA, Writing Committee Member, Mark H. Drazner, MD, MSc, FACC, FAHA,
Writing Committee Member, Gerasimos Filippatos, MD, FESC, Writing Committee
Member, Gregg C. Fonarow, MD, FACC, FAHA, FHFSA, Writing Committee Member,
Michael M. Givertz, MD, FACC, FHFSA, Writing Committee Member, Steven M.
Hollenberg, MD, FACC, Writing Committee Member, JoAnn Lindenfeld, MD, FACC,
FAHA, FHFSA, Writing Committee Member, Frederick A. Masoudi, MD, MSPH,
FACC, Writing Committee Member, Patrick E. McBride, MD, MPH, FACC, Writing
Committee Member, Pamela N. Peterson, MD, FACC, Writing Committee Member,
Lynne Warner Stevenson, MD, FACC, Writing Committee Member, Cheryl Westlake,
PhD, RN, ACNS-BC, FHFSA, Writing Committee Member
PII:
S0735-1097(16)33024-8
DOI:
10.1016/j.jacc.2016.05.011
Reference:
JAC 22576
To appear in:
Journal of the American College of Cardiology
Please cite this article as: Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, Drazner
MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride
PE, Peterson PN, Stevenson LW, Westlake C, 2016 ACC/AHA/HFSA Focused Update on New
Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the
Management of Heart Failure, Journal of the American College of Cardiology (2016), doi: 10.1016/
j.jacc.2016.05.011.
Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
Heart Failure Focused Update on Pharmacological Therapy
RI
PT
2016 ACC/AHA/HFSA Focused Update on New Pharmacological

Therapy for Heart Failure: An Update of the 2013 ACCF/AHA
Guideline for the Management of Heart Failure
A Report of the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines and the Heart Failure Society of America
Developed in Collaboration With the International Society for Heart and Lung
Transplantation
SC
WRITING COMMITTEE MEMBERS*
TE
D
M
AN
U
Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair

Mariell Jessup, MD, FACC, FAHA, FESC, Vice Chair
Biykem Bozkurt, MD, PhD, FACC, FAHA
Steven M. Hollenberg, MD, FACC#
Javed Butler, MD, MBA, MPH, FACC, FAHA
JoAnn Lindenfeld, MD, FACC, FAHA, FHFSA
Donald E. Casey, Jr, MD, MPH, MBA, FACC
Frederick A. Masoudi, MD, MSPH, FACC**
Monica M. Colvin, MD, FAHA
Patrick E. McBride, MD, MPH, FACC
Mark H. Drazner, MD, MSc, FACC, FAHA
Pamela N. Peterson, MD, FACC
Gerasimos Filippatos, MD, FESC
Lynne Warner Stevenson, MD, FACC
Gregg C. Fonarow, MD, FACC, FAHA, FHFSA
Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA
Michael M. Givertz, MD, FACC, FHFSA
ACC/AHA TASK FORCE MEMBERS
AC
C
EP
Jonathan L. Halperin, MD, FACC, FAHA, Chair

Glenn N. Levine, MD, FACC, FAHA, Chair-Elect
Sana M. Al-Khatib, MD, MHS, FACC, FAHA
Federico Gentile, MD, FACC
Kim K. Birtcher, PharmD, MS, AACC
Samuel Gidding, MD, FAHA
Biykem Bozkurt, MD, PhD, FACC, FAHA
Mark A. Hlatky, MD, FACC
Ralph G. Brindis, MD, MPH, MACC
John Ikonomidis, MD, PhD, FAHA
Joaquin E. Cigarroa, MD, FACC
Jos Joglar, MD, FACC, FAHA
Lesley H. Curtis, PhD, FAHA
Susan J. Pressler, PhD, RN, FAHA
Lee A. Fleisher, MD, FACC, FAHA
Duminda N. Wijeysundera, MD, PhD
*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with
industry may apply; see Appendix 1 for detailed information.
ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ACC/AHA Representative. ACP Representative. ISHLT
Representative. HFSA Representative. #CHEST Representative. **ACC/AHA Task Force on Performance Measures
Representative. AAFP Representative.
This document was approved by the American College of Cardiology Board of Trustees and Executive Committee, the American
Heart Association Science Advisory and Coordinating Committee and Executive Committee, and the Heart Failure Society of
America Executive Committee in April 2016.
The American College of Cardiology requests that this document be cited as follows: Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA,
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy
for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure
Society of America. J Am Coll Cardiol. 2016;:.
This article has been copublished in Circulation and the Journal of Cardiac Failure.
RI
PT
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the
American Heart Association (professional.heart.org), and the Heart Failure Society of America (www.hfsa.org). For copies of
this document, please contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail (reprints@elsevier.com).
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted
without the express permission of the American College of Cardiology. Requests may be completed online via the Elsevier site
(http://www.elsevier.com/about/policies/author-agreement/obtaining-permission).
AC
C
EP
TE
D
M
AN
U
SC
2016 by the American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society
of America.
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
Table of Contents
Preamble ...................................................................................................................................................... 4
RI
PT
Introduction................................................................................................................................................. 6
7.3. Stage C .................................................................................................................................................. 8
7.3.2. Pharmacological Treatment for Stage C HF With Reduced Ejection Fraction: Recommendations8
7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme Inhibitor or
SC
Angiotensin Receptor Blocker or ARNI: Recommendations ............................................................... 8

7.3.2.11. Ivabradine: Recommendation .............................................................................................. 11
M
AN
U
References .................................................................................................................................................. 13
Appendix 1. Author Relationships With Industry and Other Entities (Relevant) ............................ 16
AC
C
EP
TE
D
Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) ............. 19
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
Preamble
RI
PT
Incorporation of new study results, medications, or devices that merit modification of existing clinical
practice guideline recommendations, or the addition of new recommendations, is critical to ensuring that
guidelines reflect current knowledge, available treatment options, and optimum medical care. To keep
pace with evolving evidence, the American College of Cardiology (ACC)/American Heart Association
(AHA) Task Force on Clinical Practice Guidelines (Task Force) has issued this focused update to
reassess guideline recommendations on the basis of recently published study data. This update has been
subject to rigorous, multilevel review and approval, similar to the full guidelines. For specific focused
update criteria and additional methodological details, please see the ACC/AHA guideline methodology
manual (1).
M
AN
U
SC
ModernizationProcesses have evolved over time in response to published reports from the Institute of
Medicine (2, 3) and ACC/AHA mandates (4-7), leading to adoption of a knowledge byte format. This
process entails delineation of a recommendation addressing a specific clinical question, followed by
concise text (ideally <250 words) and hyperlinked to supportive evidence. This approach better
accommodates time constraints on busy clinicians, facilitates easier access to recommendations via
electronic search engines and other evolving technology, and supports the evolution of guidelines as
living documents that can be dynamically updated as needed.
TE
D
Guideline-Directed Evaluation and ManagementThe term guideline-directed evaluation and

management (GDEM) refers to care defined mainly by ACC/AHA Class I recommendations. For these
and all recommended drug treatment regimens, the reader should confirm dosage with product insert
material and carefully evaluate for contraindications and interactions. Recommendations are limited to
treatments, drugs, and devices approved for clinical use in the United States.
AC
C
EP
Class of Recommendation and Level of EvidenceThe Class of Recommendation (COR) and Level of
Evidence (LOE) are derived independently of each other according to established criteria. The COR
indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit
of a clinical action in proportion to risk. The LOE rates the quality of scientific evidence supporting the
intervention on the basis of the type, quantity, and consistency of data from clinical trials and other
sources (Table 1). Recommendations in this focused update reflect the new 2015 COR/LOE system, in
which LOE B and C are subcategorized for the purpose of increased granularity (1, 5, 8).
Relationships With Industry and Other EntitiesThe ACC and AHA exclusively sponsor the work of
guideline writing committees without commercial support, and members volunteer time for this activity.
Selected organizations and professional societies with related interests and expertise are invited to
participate as partners or collaborators. The Task Force makes every effort to avoid actual, potential, or
perceived conflicts of interest that might arise through relationships with industry or other entities (RWI).
All writing committee members and reviewers are required to fully disclose current industry relationships
or personal interests, beginning 12 months before initiation of the writing effort. Management of RWI
involves selecting a balanced writing committee and requires that both the chair and a majority of writing
committee members have no relevant RWI (see Appendix 1 for the definition of relevance). Members are
restricted with regard to writing or voting on sections to which RWI apply. Members of the writing
4
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
RI
PT
committee who recused themselves from voting are indicated and specific section recusals are noted in
Appendix 1. In addition, for transparency, members comprehensive disclosure information is available as
an Online Supplement
(http://jaccjacc.acc.org/Clinical_Document/HF_Focused_Update_RWI_Table_comprehensive_S5.pdf),
and reviewers RWI disclosures are included in Appendix 2. Comprehensive disclosure information for
the Task Force is also available at http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/guidelines-and-documents-task-forces.The Task Force strives to avoid bias by selecting
experts from a broad array of backgrounds representing different geographic regions, genders, ethnicities,
intellectual perspectives, and scopes of clinical activities.
M
AN
U
SC
Intended UseGuidelines provide recommendations applicable to patients with or at risk of developing

cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in
collaboration with other organizations may have a broader target. Although guidelines may be used to
inform regulatory or payer decisions, the intent is to improve quality of care and align with patients
interests. The guidelines are reviewed annually by the Task Force and are official policy of the ACC and
AHA. Each guideline is considered current unless and until it is updated, revised, or superseded by a
published addendum.
TE
D
Related IssuesFor additional information pertaining to the methodology for grading evidence,
assessment of benefit and harm, shared decision making between the patient and clinician, structure of
evidence tables and summaries, standardized terminology for articulating recommendations,
organizational involvement, peer review, and policies regarding periodic assessment and updating of
guideline documents, we encourage readers to consult the ACC/AHA guideline methodology manual (1).
AC
C
EP
Jonathan L. Halperin, MD, FACC, FAHA

Chair, ACC/AHA Task Force on Clinical Practice Guidelines
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
Introduction
The ACC, the AHA, and the Heart Failure Society of America (HFSA) recognize that the introduction of
effective new therapies that potentially affect a large number of patients presents both opportunities and
challenges. The introduction of an angiotensin receptorneprilysin inhibitor (ARNI) (valsartan/sacubitril)
RI
PT
and a sinoatrial node modulator (ivabradine), when applied judiciously, complements established
pharmacological and device-based therapies and represents a milestone in the evolution of care for
patients with heart failure (HF). Accordingly, the writing committees of the 2016 ACC/AHA/HFSA
Focused Update on New Pharmacological Therapy for Heart Failure and the 2016 ESC Guideline on
SC
the Diagnosis and Treatment of Acute and Chronic Heart Failure concurrently developed
recommendations for the incorporation of these therapies into clinical practice. Working independently,
each writing committee surveyed the evidence, arrived at similar conclusions, and constructed similar, but
M
AN
U
not identical, recommendations. Given the concordance, the respective organizations simultaneously
issued aligned recommendations on the use of these new treatments to minimize confusion and improve
the care of patients with HF.
Members of the ACC/AHA/HFSA writing committee without relevant RWI voted on the final
recommendations. These were subjected to external peer review by 25 official, organizational, and
content reviewers before approval by the Task Force and the leadership of the ACC, AHA, and HFSA, as
TE
D
well as endorsement by the International Society for Heart and Lung Transplantation. The statements
issued by the European Society of Cardiology writing committee went through a similarly rigorous
process of external review before endorsement by the societal leadership.
No single clinical trial answers all pertinent questions, nor can trial results be perfectly replicated
EP
in clinical practice. Several critical questions remain unanswered, and further experience in both ongoing
trials and clinical therapeutics may require modification of these initial recommendations. On the basis of
the currently available evidence, however, the recommendations that follow reflect our assessment of how
AC
C
best to proceed today.
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies,

Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
7.3. Stage C
7.3.2. Pharmacological Treatment for Stage C HF With Reduced
Ejection Fraction: Recommendations
RI
PT
7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme

Inhibitor or Angiotensin Receptor Blocker or ARNI: Recommendations
See the Online Data Supplement
(http://jaccjacc.acc.org/Clinical_Document/2016_Heart_Failure_Focused_Update_Data_Supplement_Ne
SC
w_Therapy_Only_S5.pdf) for evidence supporting these recommendations.
AC
C
EP
TE
D
M
AN
U
Recommendations for Renin-Angiotensin System Inhibition With ACE Inhibitor or ARB or ARNI
COR
LOE
Recommendations
The clinical strategy of inhibition of the renin-angiotensin system with
ACE: A
ACE inhibitors (Level of Evidence: A) (9-14), OR ARBs (Level of Evidence:
A) (15-18), OR ARNI (Level of Evidence: B-R) (19) in conjunction with
ARB: A
I
evidence-based beta blockers (20-22), and aldosterone antagonists in
selected patients (23, 24), is recommended for patients with chronic HFrEF
ARNI: B-R
to reduce morbidity and mortality.
Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and
mortality in heart failure with reduced ejection fraction (HFrEF). Randomized
controlled trials (RCTs) clearly establish the benefits of ACE inhibition in
patients with mild, moderate, or severe symptoms of HF and in patients with or
without coronary artery disease (9-14). ACE inhibitors can produce angioedema
and should be given with caution to patients with low systemic blood pressures,
renal insufficiency, or elevated serum potassium. ACE inhibitors also inhibit
kininase and increase levels of bradykinin, which can induce cough but also
may contribute to their beneficial effect through vasodilation.
Angiotensin receptor blockers (ARBs) were developed with the rationale
See Online Data
that angiotensin II production continues in the presence of ACE inhibition,
Supplements 1, 2,
driven through alternative enzyme pathways. ARBs do not inhibit kininase and
18-20.
are associated with a much lower incidence of cough and angioedema than ACE
inhibitors; but like ACE inhibitors, ARBs should be given with caution to
patients with low systemic blood pressure, renal insufficiency, or elevated
serum potassium. Long-term therapy with ARBs produces hemodynamic,
neurohormonal, and clinical effects consistent with those expected after
interference with the renin-angiotensin system and have been shown in RCTs
(15-18) to reduce morbidity and mortality, especially in ACE inhibitor
intolerant patients.
In ARNI, an ARB is combined with an inhibitor of neprilysin, an enzyme
that degrades natriuretic peptides, bradykinin, adrenomedullin, and other
vasoactive peptides. In an RCT that compared the first approved ARNI,
8
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
RI
PT
ACE: A
ACE inhibitors have been shown in large RCTs to reduce morbidity and
mortality in patients with HFrEF with mild, moderate, or severe symptoms of
HF, with or without coronary artery disease (9-14). Data suggest that there are
no differences among available ACE inhibitors in their effects on symptoms or
survival (25). ACE inhibitors should be started at low doses and titrated upward
to doses shown to reduce the risk of cardiovascular events in clinical trials.
ACE inhibitors can produce angioedema and should be given with caution to
patients with low systemic blood pressures, renal insufficiency, or elevated
serum potassium (>5.0 mEq/L). Angioedema occurs in <1% of patients who
take an ACE inhibitor, but it occurs more frequently in blacks and women (26).
Patients should not be given ACE inhibitors if they are pregnant or plan to
become pregnant. ACE inhibitors also inhibit kininase and increase levels of
bradykinin, which can induce cough in up to 20% of patients but also may
contribute to beneficial vasodilation. If maximal doses are not tolerated,
intermediate doses should be tried; abrupt withdrawal of ACE inhibition can
lead to clinical deterioration and should be avoided.
Although the use of an ARNI in lieu of an ACE inhibitor for HFrEF has
been found to be superior, for those patients for whom ARNI is not appropriate,
continued use of an ACE inhibitor for all classes of HFrEF remains strongly
advised.
ARB: A
The use of ARBs to reduce morbidity and mortality is recommended in

patients with prior or current symptoms of chronic HFrEF who are
intolerant to ACE inhibitors because of cough or angioedema (15-18, 27,
28).
ARBs have been shown to reduce mortality and HF hospitalizations in patients
with HFrEF in large RCTs (15-18). Long-term therapy with ARBs in patients
with HFrEF produces hemodynamic, neurohormonal, and clinical effects
consistent with those expected after interference with the renin-angiotensin
system (27, 28). Unlike ACE inhibitors, ARBs do not inhibit kininase and are
associated with a much lower incidence of cough and angioedema, although
kininase inhibition by ACE inhibitors may produce beneficial vasodilatory
effects.
Patients intolerant to ACE inhibitors because of cough or angioedema
should be started on ARBs; patients already tolerating ARBs for other
AC
C
EP
TE
D
See Online Data

Supplement 18.
M
AN
U
SC
valsartan/sacubitril, with enalapril in symptomatic patients with HFrEF

tolerating an adequate dose of either ACE inhibitor or ARB, the ARNI reduced
the composite endpoint of cardiovascular death or HF hospitalization
significantly, by 20% (19). The benefit was seen to a similar extent for both
death and HF hospitalization and was consistent across subgroups. The use of
ARNI is associated with the risk of hypotension and renal insufficiency and
may lead to angioedema, as well.
The use of ACE inhibitors is beneficial for patients with prior or current
symptoms of chronic HFrEF to reduce morbidity and mortality (9-14, 25).
See Online Data

Supplements 2 and
19.
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
AC
C
EP
See Online Data

Supplements 1 and
18.
TE
D
M
AN
U
SC
ARNI: B-R
RI
PT
indications may be continued on ARBs if they subsequently develop HF. ARBs

should be started at low doses and titrated upward, with an attempt to use doses
shown to reduce the risk of cardiovascular events in clinical trials. ARBs should
be given with caution to patients with low systemic blood pressure, renal
insufficiency, or elevated serum potassium (>5.0 mEq/L). Although ARBs are
alternatives for patients with ACE inhibitorinduced angioedema, caution is
advised because some patients have also developed angioedema with ARBs.
Head-to-head comparisons of an ARB versus ARNI for HF do not exist.
For those patients for whom an ACE inhibitor or ARNI is inappropriate, use of
an ARB remains advised.
In patients with chronic symptomatic HFrEF NYHA class II or III who
tolerate an ACE inhibitor or ARB, replacement by an ARNI is
recommended to further reduce morbidity and mortality (19).
Benefits of ACE inhibitors with regard to decreasing HF progression,
hospitalizations, and mortality rate have been shown consistently for patients
across the clinical spectrum, from asymptomatic to severely symptomatic HF.
Similar benefits have been shown for ARBs in populations with mild-tomoderate HF who are unable to tolerate ACE inhibitors. In patients with mildto-moderate HF (characterized by either 1) mildly elevated natriuretic peptide
levels, BNP [B-type natriuretic peptide] >150 pg/mL or NT-proBNP [Nterminal pro-B-type natriuretic peptide] 600 pg/mL; or 2) BNP 100 pg/mL or
NT-proBNP 400 pg/mL with a prior hospitalization in the preceding 12
months) who were able to tolerate both a target dose of enalapril (10 mg twice
daily) and then subsequently an ARNI (valsartan/sacubitril; 200 mg twice daily,
with the ARB component equivalent to valsartan 160 mg), hospitalizations and
mortality were significantly decreased with the valsartan/sacubitril compound
compared with enalapril. The target dose of the ACE inhibitor was consistent
with that known to improve outcomes in previous landmark clinical trials (10).
This ARNI has recently been approved for patients with symptomatic HFrEF
and is intended to be substituted for ACE inhibitors or ARBs. HF effects and
potential off-target effects may be complex with inhibition of the neprilysin
enzyme, which has multiple biological targets. Use of an ARNI is associated
with hypotension and a low-frequency incidence of angioedema. To facilitate
initiation and titration, the approved ARNI is available in 3 doses that include a
dose that was not tested in the HF trial; the target dose used in the trial was
97/103 mg twice daily (29). Clinical experience will provide further
information about the optimal titration and tolerability of ARNI, particularly
with regard to blood pressure, adjustment of concomitant HF medications, and
the rare complication of angioedema (30).
ARNI should not be administered concomitantly with ACE inhibitors or
within 36 hours of the last dose of an ACE inhibitor (31, 32).
Oral neprilysin inhibitors, used in combination with ACE inhibitors can lead to
angioedema and concomitant use is contraindicated and should be avoided. A
medication that represented both a neprilysin inhibitor and an ACE inhibitor,
III:
Harm
B-R
See Online Data

Supplement 3.
10
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
Omapatrilat, a neprilysin inhibitor (as well as an ACE inhibitor and

aminopeptidase P inhibitor), was associated with a higher frequency of
angioedema than that seen with enalapril in an RCT of patients with HFrEF
(31). In a very large RCT of hypertensive patients, ompatrilat was associated
with a 3-fold increased risk of angioedema as compared with enalapril (32).
Blacks and smokers were particularly at risk. The high incidence of angioedema
ultimately led to cessation of the clinical development of omapatrilat (34, 35).
In light of these observations, angioedema was an exclusion criterion in the first
large trial assessing ARNI therapy in patients with hypertension (36) and then
in the large trial that demonstrated clinical benefit of ARNI therapy in HFrEF
(19). ARNI therapy should not be administered in patients with a history of
angioedema because of the concern that it will increase the risk of a recurrence
of angioedema.
M
AN
U
N/A
RI
PT
C-EO
SC
III:
Harm
omapatrilat, was studied in both hypertension and HF, but its development was
terminated because of an unacceptable incidence of angioedema (31, 32) and
associated significant morbidity. This adverse effect was thought to occur
because both ACE and neprilysin break down bradykinin, which directly or
indirectly can cause angioedema (32, 33). An ARNI should not be administered
within 36 hours of switching from or to an ACE inhibitor.
ARNI should not be administered to patients with a history of angioedema.
TE
D
7.3.2.11. Ivabradine: Recommendation

See the Online Data Supplement
(http://jaccjacc.acc.org/Clinical_Document/2016_Heart_Failure_Focused_Update_Data_Supplement_Ne
w_Therapy_Only_S5.pdf) for evidence supporting this recommendation.
AC
C
EP
Recommendation for Ivabradine

COR
LOE
Recommendation
Ivabradine can be beneficial to reduce HF hospitalization for patients with
symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF 35%) who
IIa
B-R
are receiving GDEM, including a beta blocker at maximum tolerated dose,
and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest
(37-40).
Ivabradine is a new therapeutic agent that selectively inhibits the If current in
the sinoatrial node, providing heart rate reduction. One RCT demonstrated the
efficacy of ivabradine in reducing the composite endpoint of cardiovascular
See Online Data
death or HF hospitalization (38). The benefit of ivabradine was driven by a
Supplement 4.
reduction in HF hospitalization. The study included patients with HFrEF
(NYHA class II-IV, albeit with only a modest representation of NYHA class IV
HF) and left ventricular ejection fraction (LVEF) 35%, in sinus rhythm with a
resting heart rate of 70 beats per minute. Patients enrolled included a small
number with paroxysmal atrial fibrillation (<40% of the time) but otherwise in
11
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
RI
PT
sinus rhythm and a small number experiencing ventricular pacing but with a
predominant sinus rhythm. Those with a myocardial infarction within the
preceding 2 months were excluded. Patients enrolled had been hospitalized for
HF in the preceding 12 months and were on stable GDEM for 4 weeks before
initiation of ivabradine therapy. The target of ivabradine is heart rate slowing
(the presumed benefit of action), but only 25% of patients studied were on
optimal doses of beta-blocker therapy (20-22, 38). Given the well-proven
mortality benefits of beta-blocker therapy, it is important to initiate and up
titrate these agents to target doses, as tolerated, before assessing the resting
heart rate for consideration of ivabradine initiation (38).
Presidents and Staff

American College of Cardiology
M
AN
U
SC
The remainder of the 2016 ACC/AHA/HFSA Focused Update on the Management of Heart Failure: An
Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure will be forthcoming.
Richard A. Chazal, MD, FACC, President

Shalom Jacobovitz, Chief Executive Officer
William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and
Publications
Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing
TE
D
American College of Cardiology/American Heart Association
EP
Melanie Stephens-Lyman, MSc, Director, Guideline Operations and Strategy

Lisa Bradfield, CAE, Director, Guideline Methodology and Policy
Abdul R. Abdullah, MD, Associate Science and Medicine Advisor
Morgane Cibotti-Sun, MPH, Project Manager, Clinical Practice Guidelines
American Heart Association
AC
C
Mark A. Creager, MD, FACC, FAHA, President

Nancy Brown, Chief Executive Officer
Rose Marie Robertson, MD, FAHA, Chief Science and Medical Officer
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations
Comilla Sasson, MD, PhD, FACEP, Vice President, Science and Medicine
Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations
Key Words: ACC/AHA Clinical Practice Guidelines Heart Failure Focused Update Angiotensin
Receptor-Neprilysin Inhibitor Ivabradine Angiotensin Receptor Blockers Angiotensin-Converting
Enzyme Inhibitors Beta blockers Angioedema Natriuretic Peptides
12
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
References
1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
RI
PT
SC
M
AN
U
5.
TE
D
4.
EP
3.
AC
C
2.
Task Force on Practice Guidelines. Available at:

http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and
http://my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/documents/downloadable/ucm_319826.pdf. 2010; American College of Cardiology
and American Heart Association. Accessed April 7, 2016.
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine
(U.S.). Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of
Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC:
National Academies Press; 2011.
Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit
report: a report of the American College of Cardiology Foundation/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol. 2013;61:213-65.
Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/AHA clinical practice guidelines:
a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol. 2014;64:1373-84.
Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in
clinical practice guidelines and performance measures: a report of the American College of
Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice
Guidelines. J Am Coll Cardiol. 2014;63:2304-22.
Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical
practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American
Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J
Am Coll Cardiol. 2014;64:1851-6.
Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice
guideline recommendation classification system: a report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;67:1572-4.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J
Med. 1987;316:1429-35.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive
heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.
ATLAS Study Group. Circulation. 1999;100:2312-8.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with
left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement
trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical
evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet.
1993;342:821-8.
Kber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor
trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac
Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-6.
Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction
complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical
outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet.
2009;374:1840-8.
13
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
18. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients
with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.
19. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart
failure. N Engl J Med. 2014;371:993-1004.
20. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
21. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe
chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS)
study. Circulation. 2002;106:2194-9.
22. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a
report of the American College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.
23. Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk
for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups
(Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol.
2013;62:1585-93.
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med.
1999;341:709-17.
25. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality
and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA.
1995;273:1450-6.
26. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. Sex-dependent and race-dependent association of
XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.
Pharmacogenet Genomics. 2010;20:532-6.
27. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators. N Engl J Med. 2008;358:1547-59.
28. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on
cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a
randomised controlled trial. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with
cardiovascular Disease (TRANSCEND) Investigators. Lancet. 2008;372:1174-83.
29. Entresto [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure
with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet.
2012;380:1387-95.
31. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic
heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events
(OVERTURE). Circulation. 2002;106:920-6.
32. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the
Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-11.
33. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the
treatment of heart failure. JACC Heart Fail. 2014;2:663-70.
34. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-9.
35. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart
failure. J Am Coll Cardiol. 2015;65:1029-41.
36. Ruilope LM, Dukat A, Bhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting
inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled,
active comparator study. Lancet. 2010;375:1255-66.
37. Bhm M, Robertson M, Ford I, et al. Influence of Cardiovascular and Noncardiovascular Co-morbidities
on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from
the SHIFT Trial). Am J Cardiol. 2015;116:1890-7.
38. Swedberg K, Komajda M, Bhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a
randomised placebo-controlled study. Lancet. 2010;376:875-85.
39. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N
Engl J Med. 2014;371:1091-9.
14
ACCEPTED MANUSCRIPT
Yancy, CW, et al.
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
40. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular
systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet.
2008;372:807-16.
15
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

Appendix 1. Author Relationships With Industry and Other Entities (Relevant)2016 ACC/AHA/HFSA
Focused Update on New Pharmacological Therapy for Heart Failure (December 2015)
Northwestern University Feinberg

School of Medicine, Division of
Cardiology Professor of
Medicine and Chief; Diversity and
InclusionVice Dean
University of Pennsylvania
Professor of Medicine
Michael E. DeBakey VA Medical
CenterThe Mary and Gordon
Cain Chair and Professor of
Medicine
Stony Brook UniversityDivision
Chief of Cardiology
Ownership/
Partnership
/ Principal
Personal Research
None
Institutional,
Organizational,
or Other
Financial Benefit
None
Expert
Witness
Voting
Recusals By
Section*
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Novartis
None
None
7.3.2.10 and
7.3.2.11.
Bayer
CardioCell
Medtronic
Merck
Novartis
Relypsa
Takeda
Trevena
Z Pharma
Zensun
None
Novartis
None
Amgen (DSMB)
None
None
7.3.2.10 and
7.3.2.11.
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Trevena
None
DCRI/Otsuka
UptoDate
None
None
None
None
None
Bayer
None
None
7.3.2.10 and
None
Monica M.
Colvin
Mark H. Drazner
Gerasimos S.
Thomas Jefferson College of

Population HealthAdjunct
Faculty; Alvarez & Marsal
IPO4HealthPrincipal and
Founder
University of MichiganAssociate
Professor of Medicine, Cardiology
University of Texas Southwestern
Medical CenterProfessor,
Internal Medicine
National and Kapodistrian
AC
C
Donald E. Casey,
Jr
EP
TE
D
Javed Butler
Speakers
Bureau
RI
PT
Clyde W. Yancy
(Chair)
Mariell Jessup
(Vice Chair)
Biykem Bozkurt
Consultant
SC
Employment
M
AN
U
Committee
Member
16
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

JoAnn
Lindenfeld
Frederick A.
Masoudi
Patrick E.
McBride
Pamela N.
Peterson
Lynne W.
Stevenson
University of Colorado, Denver

Associate Professor of Medicine,
Division of Cardiology
University of Wisconsin School of
Medicine and Public Health
Professor of Medicine and Family
Medicine; Associate Director,
Preventive Cardiology
University of Colorado, Denver
Health Medical CenterAssociate
Professor of Medicine, Division of
Cardiology
Brigham and Womens Hospital
Cardiovascular Division
Director, Cardiomyopathy and
Heart Failure Program
None
None
None
None
None
None
None
7.3.2.10 and
7.3.2.11.
None
None
None
None
None
None
7.3.2.10 and
7.3.2.11.
None
RI
PT
None
7.3.2.11.
Abbott
Janssen
Pharmaceuticals
Novartis
Relypsa
ResMed
None
None
None
AstraZeneca
Novartis
None
None
7.3.2.10 and
7.3.2.11.
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Novartis
PARENT trial
(PI)
NHLBI
INTERMACS
(CoPI)
None
None
7.3.2.10 and
7.3.2.11.
None
AC
C
Michael M.
Givertz
Steven M.
Hollenberg
Amgen
Janssen
Pharmaceuticals
Novartis
Merck
Novartis
None
Bayer (DSMB)
Novartis
Servier
Pharmaceuticals
Vifor
Novartis
SC
Ahmanson-UCLA
Cardiomyopathy Center
Director; UCLA Division of
CardiologyCo-Chief
Brigham and Women's Hospital
Cooper University Hospital
Director, Coronary Care Unit,
Vanderbilt Heart and Vascular
InstituteDirector, Advanced
Heart Failure and Transplant
SectionProfessor of Medicine
M
AN
U
Gregg C.
Fonarow
TE
D
University of Athens; Attikon

University Hospital, Department of
Cardiology, Heart Failure Unit
Professor of Cardiology
EP
Filippatos
None
17
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

None
None
None
None
None
None
None
Azusa Pacific University
Professor and Associate Dean,
International and Community
Programs
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were
reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily
reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting
stock or share of the business entity, or ownership of $5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of
the persons gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are
modest unless otherwise noted.
SC
RI
PT
Cheryl Westlake
M
AN
U
According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic,
or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing
drug or device addressed in the document; or c) the person or a member of the persons household has a reasonable potential for financial, professional, or other personal gain or loss
as a result of the issues/content addressed in the document.
*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.
Significant relationship.
AC
C
EP
TE
D
ACC indicates American College of Cardiology; AHA, American Heart Association; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HFSA,
Heart Failure Society of America; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.
18
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)2016

ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure (March 2016)
Employment
Consultant
Speakers
Bureau
Ownership/
Partnership/
Principal
Personal Research
None
None
Kim K.
Birtcher
Official
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
University of Houston
College of Pharmacy
Clinical Professor
Jones &
Bartlett
Learning
None
Akshay S.
Desai
Official
ReviewerHFSA
Medscape
Cardiology*
Merck
Novartis*
Relypsa*
St. Jude
Medical*
None
Anita Deswal
Official
ReviewerAHA
Dipti
Itchhaporia
Official
ReviewerACC
Board of Trustees
Ileana L. Pia
Official
ReviewerAHA
Brigham and Women's

HospitalDirector, Heart
Failure Disease
Management, Advanced
Heart Disease Section,
Cardiovascular Division;
Associate Professor of
Medicine, Harvard
Medical School
Michael E. DeBakey VA
Medical Center
Associate Chief of
Cardiology; Director,
Heart Failure Program;
Baylor College of
MedicineProfessor of
Medicine
Newport Coast
CardiologyRobert and
Georgia Roth Endowed
Chair for Excellence in
Cardiac Care; Director of
Disease Management
Montefiore Medical
CenterAssociate Chief
for Academic Affairs,
Cardiology
RI
PT
Representation
SC
Reviewer
Expert
Witness
None
None
Novartis*
Thoratec
None
None
None
NIH*
AHA
AHA (GWTG
Steering
Committee)
HFSA
None
None
None
None
None
St. Jude Medical
None
Relypsa
None
None
None
None
None
TE
D
M
AN
U
None
None
EP
AC
C
Institutional,
Organizational, or
Other Financial
Benefit
None
19
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

James E.
Udelson
Official
ReviewerHFSA
Mary Norine
Walsh
Official
ReviewerACC
Board of Trustees
David A.
Baran
Organizational
ReviewerISHLT
Kenneth
Casey
Organizational
Reviewer
CHEST
M. Fuad Jan
Organizational
Reviewer
CHEST
Organizational
University of MissouriKansas City School of

MedicineProfessor of
Pediatrics; Children's
Mercy HospitalPediatric
Cardiology
Tufts Medical Center
Chief, Division of
Cardiology
None
None
None
Lantheus
Medical
Imaging
None
None
None
RI
PT
Official
ReviewerACC
Board of
Governors
Gilead (DSMB)
GlaxoSmithKline
(DSMB)
NHLBI
Otsuka
Kenneth W.
None
AC
C
Georgetown University
None
None
Abbott
Laboratories
(Eligibility
Committee)
AHA*
Circulation/
Circulation: Heart
Failure
HFSA (Executive
Council)
Pfizer/
GlaxoSmithKline
(Clinical Events
Committee)
Sunshine Heart
(Eligibility
Committee)
Corvia Medical
Otsuka
PCORI
Thoratec
None
None
None
ACCP
None
None
None
None
Maquet
Otsuka*
Novartis
None
None
None
None
XDxIMAGE
trial (Steering
Committee)*
NIH*
None
None
None
None
None
None
None
None
None
None
None
None
None
EP
St Vincent Heart Center of

IndianaMedical
Director, Heart Failure and
Cardiac Transplantation
Newark Beth Israel
Medical CenterDirector
of Heart Failure and
Transplant Research
Wm. S. Middleton
Memorial Veterans
HospitalDirector, Sleep
Medicine
Aurora Advanced
HealthcareCardiologist
TE
D
M
AN
U
SC
Geetha
Raghuveer
20
None
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

Joaquin E.
Cigarroa
Content
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
School of Medicine
Clinician Educator Track,
Associate Professor
Oregon Health & Science
UniversityClinical
None
None
None
None
RI
PT
ReviewerAAFP
James L.
Januzzi
Jos A. Joglar
Content
Blue Cross/
Blue Shield*
NQF
Yale
University
TE
D
Content
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
Content Reviewer
University of Pennsylvania
Health SystemRobert
Dunning Dripps Professor
of Anesthesiology and
Critical Care; Chair,
Department of
Anesthesiology & Critical
Care
Nemours/Alfred I. duPont
Hospital for Children
Chief, Division of Pediatric
Cardiology
None
None
Johns Hopkins
(DSMB)
ACC/AHA
AHA
ASA
Catheterization and
Cardiovascular
Intervention
NIH
Portland Metro
Area AHA
(President)
SCAI Quality
Interventional
Council
Association of
University
Anesthesiologists
NIH
None
None
FH
Foundation
International
FH
Foundation
None
None
FH Foundation
NIH*
None
None
Massachusetts General
HospitalHutter Family
Professor of Medicine in
the Field of Cardiology
Critical
Diagnostics*
Novartis*
Phillips
Roche
Diagnostics*
Sphingotec*
None
None
None
None
UT Southwestern Medical
None
None
None
Amgen (DSMB)
Boeringer
Ingelheim
(DSMB)*
Janssen
Pharmaceuticals
(DSMB)
Prevencio*
None
None
None
EP
Samuel S.
Gidding
Content
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
AC
C
Lee A.
Fleisher
M
AN
U
SC
Lin
21
ACCEPTED MANUSCRIPT
Sean P.
Pinney
Content
ReviewerACC
Heart Failure and
Transplant Council
Content
ReviewerACC
Heart Failure and
Transplant Council
Randall C.
Starling
W. H. Wilson
Tang
Content Reviewer
SUNY Downstate Medical

CenterDirector/Heart
Failure Center; SUNY
Downstate College of
MedicineAssociate
Mount Sinai School of
MedicineAssociate
Professor of Medicine,
Cardiology
Cleveland Clinic
Department of
Cardiovascular
MedicineVice
Chairman, Department of
Cardiovascular Medicine;
Section Head, Heart
Failure & Cardiac
Transplant
Cleveland Clinic
FoundationAssistant
None
None
None
Abbott
Laboratories
Biotronik
GE Healthcare
HeartWare
PharminIN
None
None
None
NIH
Novartis*
St. Jude
Medical*
None
SC
Content Reviewer
None
M
AN
U
Judith E.
Mitchell
None
Amgen*
AHA
HeartWare*
Novartis*
Resmed*
Thoratec
Association of
Black
Cardiologists
None
None
None
Acorda
Therapeutics
Thoratec
XDx
BioControl
Medtronic
Novartis
None
None
Thoratec
NIH
None
None
None
None
St. Jude Medical
None
None
None
None
NIH*
Alnylam
Pharmaceuticals
NIH
NHLBI
Roche
None
TE
D
Content Reviewer
None
EP
Wayne C.
Levy
CenterProfessor of
Internal Medicine; Clinical
Cardiac
Electrophysiology
Program Director
Johns Hopkins
CardiologyE. Cowles
Andrus Professor in
Cardiology
University of
WashingtonProfessor of
Medicine
AC
C
Edward K.
Kasper
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
Content Reviewer
RI
PT
Yancy, CW, et al.

22
Medtronic
NIH*
Novartis
St. Jude
Medical
None
ACCEPTED MANUSCRIPT
Yancy, CW, et al.

Content Reviewer
Columbia University
College of Physicians &
SurgeonsAssistant
Professor, Section of
Cardiology
Li Ka Shing Knowledge
Institute of St. Michaels
HospitalScientist;
University of Toronto
Assistant Professor,
Department of Anesthesia
and Institute of Health
Policy Management and
Evaluation
None
None
None
Bayer
Bristol-Myers
Squib
NHLBI*
None
RI
PT
Emily J. Tsai
Novartis
Thoratec
None
None
None
CIHR (DSMB)
CIHR*
Heart and Stroke
Foundation of
Canada*
Ministry of
Health & Longterm Care of
Ontario*
PCORI
(DSMB)
This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to
this document. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the
interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5,000 of the fair market value of the business entity, or if funds
received by the person from the business entity exceed 5% of the persons gross income for the previous year. A relationship is considered to be modest if it is less than
significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are
modest unless otherwise noted. Names are listed in alphabetical order within each category of review.
American College of Physicians did not provide a peer reviewer for this document.
*Significant relationship.
No financial benefit.
None
None
M
AN
U
SC
None
TE
D
Content
Reviewer
ACC/AHA Task
Force on Clinical
Practice
Guidelines
EP
Duminda N.
Wijeysundera
AC
C
AAFP indicates American Academy of Family Physicians; ACC, American College of Cardiology; AHA, American Heart Association; ASA, American Stroke Association;
CHEST, American College of Chest Physicians; CIHR, Canadian Institutes of Health Research; DSMB, data safety monitoring board; FH, familial hypercholesterolemia;
GWTG, Get With The Guidelines; HFSA, Heart Failure Society of America; ISHLT, International Society for Heart and Lung Transplantation; NIH, National Institutes of
Health; NHLBI, National Heart, Lung, and Blood Institute; NQF, National Quality Forum; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiac
Angiography and Interventions; SUNY, State University of New York; UT, University of Texas; and VA, Veterans Affairs.
23

2016 ACC AHA HFSA Guideline Update

Transféré par

Informations du document

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

2016 ACC AHA HFSA Guideline Update

Transféré par

Droits d'auteur :

Formats disponibles

Accepted Manuscript

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart

Journal of the American College of Cardiology

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

2016 ACC/AHA/HFSA Focused Update on New Pharmacological

WRITING COMMITTEE MEMBERS*

Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair

ACC/AHA TASK FORCE MEMBERS

Jonathan L. Halperin, MD, FACC, FAHA, Chair

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Angiotensin Receptor Blocker or ARNI: Recommendations ............................................................... 8

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Guideline-Directed Evaluation and ManagementThe term guideline-directed evaluation and

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Intended UseGuidelines provide recommendations applicable to patients with or at risk of developing

Jonathan L. Halperin, MD, FACC, FAHA

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

best to proceed today.

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies,

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme

w_Therapy_Only_S5.pdf) for evidence supporting these recommendations.

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

The use of ARBs to reduce morbidity and mortality is recommended in

See Online Data

valsartan/sacubitril, with enalapril in symptomatic patients with HFrEF

See Online Data

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

See Online Data

indications may be continued on ARBs if they subsequently develop HF. ARBs

See Online Data

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Omapatrilat, a neprilysin inhibitor (as well as an ACE inhibitor and

7.3.2.11. Ivabradine: Recommendation

Recommendation for Ivabradine

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Presidents and Staff

Richard A. Chazal, MD, FACC, President

American College of Cardiology/American Heart Association

Melanie Stephens-Lyman, MSc, Director, Guideline Operations and Strategy

Mark A. Creager, MD, FACC, FAHA, President

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Task Force on Practice Guidelines. Available at:

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Yancy, CW, et al.

Northwestern University Feinberg

Thomas Jefferson College of

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Yancy, CW, et al.

University of Colorado, Denver

University of Athens; Attikon

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Yancy, CW, et al.

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016

Yancy, CW, et al.

Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)2016

Brigham and Women's

St. Jude Medical

Downloaded From: http://content.onlinejacc.org/ by Rapeephon Kunjara-Na-Ayudhya on 05/20/2016